<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26885">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02095015</url>
  </required_header>
  <id_info>
    <org_study_id>SHP-001-801</org_study_id>
    <nct_id>NCT02095015</nct_id>
  </id_info>
  <brief_title>Mucopolysaccharidosis (MPS) I, II, and VI Screening in a High-Risk Population With Previous Surgical Repair or Presence of Inguinal and/or Umbilical Hernia in Combination With Pediatric ENT Surgery (The HATT Project)</brief_title>
  <official_title>Mucopolysaccharidosis (MPS) I, II, and VI Screening in a High Risk Population With Previous Surgical Repair or Presence of Inguinal and/or Umbilical Hernia in Combination With Pediatric Ear, Nose and Throat (ENT) Surgery (Adenoidectomy and/or Tonsillectomy and/or Tympanostomy) (The HATT Project)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Germany: Ethics Commission</authority>
    <authority>Italy: Ethics Committee</authority>
    <authority>Mexico: Federal Commission for Sanitary Risks Protection</authority>
    <authority>Russia: Ethics Committee</authority>
    <authority>Spain: Ethics Committee</authority>
    <authority>Turkey: Ministry of Health</authority>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mucopolysaccharidosis (MPS) type II (MPS II; Hunter syndrome) is a rare, X-linked disease
      caused by a deficiency of the lysosomal enzyme iduronate-2-sulfatase (I2S) and occurs almost
      exclusively in boys, with an incidence of approximately 1.3 per 100,000 live male births.1
      Early identification of MPS II is challenging because some initial features, such as chronic
      runny nose, otitis media, and hernias, are commonly seen in the general population. As a
      result, even though the signs and symptoms of MPS II typically appear early in childhood,
      the diagnosis may lag behind by several years.

      The primary objective of this international multi-center study is to evaluate the positive
      screening rate of MPS II subjects by screening a high-risk male pediatric population who
      have had or are scheduled for 1 or more specific ENT surgical procedures (adenoidectomy
      and/or tonsillectomy and/or tympanostomy) and who have a previously repaired or present
      evidence of an inguinal and/or umbilical hernia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With evidence-based information from MPS registries regarding the types of surgical
      interventions that are most prevalent in MPS, this screening study is expected to provide
      the understanding of the role pediatric ENT surgeons can play in identifying young children
      with MPS.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>The status of diagnosis of MPS II (either positive or negative) of each subject</measure>
    <time_frame>Screening visit</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the positive screening rate of MPS II subjects by screening a high risk male pediatric population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The status of diagnosis of MPS I or VI (either positive or negative) of each subject</measure>
    <time_frame>Screening visit</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Mucopolysaccharidosis</condition>
  <condition>Mucopolysaccharidosis I</condition>
  <condition>Mucopolysaccharidosis II</condition>
  <condition>Mucopolysaccharidosis VI</condition>
  <arm_group>
    <arm_group_label>Analysis population</arm_group_label>
    <description>All subjects enrolled in the study who meet the eligibility criteria</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Males of any ethnic background or race, &lt;7 years of age or under, who have had or are
        scheduled for adenoidectomy and/or tonsillectomy and/or tympanostomy (alone or in
        combination), will be enrolled. In addition, the subjects must have previous surgical
        repair or presence of inguinal and/or umbilical hernia.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Each subject must meet the following criteria to be enrolled in this study:

          1. The subject is male.

          2. The subject is &lt;7 years of age.

          3. The subject has had or is scheduled for ENT surgery for any of the following, alone
             or in combination: adenoidectomy, tonsillectomy, and tympanostomy.

          4. The subject has record of previous surgical repair or presence of inguinal and/or
             umbilical hernia.

          5. The subject's parent(s) or the subject's legally authorized representative(s) has
             provided written informed consent that has been approved by the Institutional Review
             Board/Independent Ethics Committee (IRB/IEC).

        Exclusion Criteria:

        Subjects who meet any of the following criteria will be excluded from the study:

          1. The subject has a current confirmed diagnosis of any MPS disorder.

          2. The subject was born prematurely (defined as born before 37 weeks gestation).

          3. The subject has received a blood transfusion within the past 6 weeks.

          4. The subject has received a bone marrow transplant.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>7 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tom Pulles, MD</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MedInfo Shire</last_name>
    <phone>1-866-888-0660</phone>
    <email>US_ShireHGT_Medicalinformation@shire.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olaf Bodamer, MD, PhD</last_name>
      <phone>305-243-6056</phone>
      <email>obodamer@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Olaf Bodamer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Louis Children's Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Molter, MD</last_name>
      <phone>314-454-6162</phone>
      <email>molterd@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>David Molter</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerard Vockley, MD</last_name>
      <phone>412-692-7746</phone>
      <email>gerard.vockley@chp.edu</email>
    </contact>
    <investigator>
      <last_name>Gerald Vockley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BC Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fred Kozak, MD</last_name>
      <phone>(604) 875-2113</phone>
      <email>fkozak@cw.bc.ca</email>
    </contact>
    <investigator>
      <last_name>Fred Kozak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arne Böttcher, MD</last_name>
      <phone>+4930450555900</phone>
      <email>arne.boettcher@charite.de</email>
    </contact>
    <investigator>
      <last_name>Arne Böttcher</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Werner Garavello, MD</last_name>
      <phone>+390392333625</phone>
      <email>werner.garavello@unimib.it</email>
    </contact>
    <investigator>
      <last_name>Werner Garavello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gesù</name>
      <address>
        <city>Palidoro</city>
        <zip>00050</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pier Marco Bianchi, MD</last_name>
      <phone>+390668593319</phone>
      <email>piermarco.bianchi@opbg.net</email>
    </contact>
    <investigator>
      <last_name>Pier Marco Bianchi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christus Muguerza del Parque, S.A. de C.V.</name>
      <address>
        <city>Chihuahua</city>
        <zip>31000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Victor Belalcazar-López, MD</last_name>
      <phone>+52614155791</phone>
      <email>victorbelalcazar@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Victor Belalcazar-López</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Center of Children's Health</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leila Namazova-Baranova, MD</last_name>
      <phone>+74959671420</phone>
      <email>namazova@nczd.ru</email>
    </contact>
    <investigator>
      <last_name>Leila Namazova-Baranova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Cruces</name>
      <address>
        <city>San Vicente de Baracaldo</city>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luis Jose Aldamiz-Echevarria Azuara, MD</last_name>
      <phone>+34946006327</phone>
      <email>luisjose.aldamiz-echevarazuara@osakidetza.net</email>
    </contact>
    <investigator>
      <last_name>Luis Jose Aldamiz-Echevarria Azuara</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hacettepe Universitesi Tip Fakultesi Hastanesi</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mehmet Akyol, MD</last_name>
      <phone>+903123051785</phone>
      <email>uakyol@hacettepe.edu.tr</email>
    </contact>
    <investigator>
      <last_name>Mehmet Akyol</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Acibadem Maslak Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>34457</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Faruk Unal, MD</last_name>
      <phone>+0902123044449</phone>
      <email>omer.unal@acibadem.edu.tr</email>
    </contact>
    <investigator>
      <last_name>Faruk Unal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karadeniz Teknik Üniversitesi (KTÜ) Saglik Uygulama Arastirma Merkezi Farabi Hastanesi</name>
      <address>
        <city>Trabzon</city>
        <zip>61080</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ahmet Ural, MD</last_name>
      <phone>+904623775883</phone>
      <email>ahmetural2001@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Ahmet Ural</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Children's Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Iain Bruce, MD</last_name>
      <phone>+441612322261</phone>
      <email>iain.bruce@cmft.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Iain Bruce</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>March 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MPS</keyword>
  <keyword>Mucopolysaccharidosis</keyword>
  <keyword>MPS I</keyword>
  <keyword>Mucopolysaccharidosis I</keyword>
  <keyword>Hurler, Hurler-Scheie, or Scheie syndrome</keyword>
  <keyword>MPS II</keyword>
  <keyword>Mucopolysaccharidosis II</keyword>
  <keyword>Hunter syndrome</keyword>
  <keyword>MPS VI</keyword>
  <keyword>Mucopolysaccharidosis VI</keyword>
  <keyword>Maroteaux-Lamy syndrome</keyword>
  <keyword>iduronate-2-sulfatase</keyword>
  <keyword>ENT</keyword>
  <keyword>ear, nose and throat</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hernia, Umbilical</mesh_term>
    <mesh_term>Mucopolysaccharidosis I</mesh_term>
    <mesh_term>Mucopolysaccharidoses</mesh_term>
    <mesh_term>Mucopolysaccharidosis II</mesh_term>
    <mesh_term>Mucopolysaccharidosis VI</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
